Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > REGULATORY
REGULATORY
- Limit Coverage of Off-Year Re-Pricing to Drugs with Large-than-Average Price Gap: LDP Proposal
November 29, 2022
- Sanofi’s Cemiplimab Backed for Approval, Third PD-1 Inhibitor in Japan
November 29, 2022
- MHLW to Report Responses to Zolgensma Paper Retraction on Dec. 12
November 29, 2022
- MHLW Panel Endorses Teikoku’s Donepezil Tape for Alzheimer’s and More Drugs
November 28, 2022
- LDP Lawmakers’ League Holds Hearing on SaMD Review Status
November 28, 2022
- Japan to Begin Xocova Supply on Nov. 28 ahead of Schedule
November 28, 2022
- MHLW Panel OKs 111 More Health Damage Claims for COVID-19 Vaccines
November 28, 2022
- Japan Approves Label Expansion for Enhertu, TS-1, and More
November 25, 2022
- Upper House Health Committee OKs Bill to Amend Infectious Disease Act
November 25, 2022
- LDP Pharma Study Group Calls for Careful Discussions on Off-Year Plan: Proposal
November 25, 2022
- LDP Lawmakers’ League Boots Up for Medical Adhesive Patches
November 24, 2022
- LDP League Urges MEXT to Provide Accurate Info on HPV Vaccines at Medical Schools
November 24, 2022
- MOF Panel Proposal Expected to Spell Out Full Annual Price Revision
November 24, 2022
- Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
- Defense Buildup Won’t Impact Degree of Cuts in Social Security Costs: MHLW Official
November 22, 2022
- Bill to Amend Intractable Disease Law Passes Lower House
November 22, 2022
- Enough Antipyretic Analgesic Agents Secured for Twindemic, MHLW Says
November 21, 2022
- LDP Tax Council to Compile FY2023 Reform Proposal by Mid-December
November 21, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
- Chuikyo Reps Tussle over Product Coverage Threshold for Off-Year Price Revision
November 17, 2022
ページ
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…